NorthCoast Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

NorthCoast Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-4,195	Closed	-$402K	–	421
2020 Q4	$402K	Sell	4,195 -2,732	-39%	-$264K	0.02%	280
2020 Q3	$666K	Buy	6,927 +267	+4%	+$30.9K	0.03%	223
2020 Q2	$813K	Sell	6,660 -1,362	-17%	-$151K	0.05%	186
2020 Q1	$694K	Buy	+8,022	New	+$785K	0.04%	183
2018 Q4	–	Sell	-180,397	Closed	-$22.2M	–	254
2018 Q3	$22.2M	Buy	+180,397	New	+$20.5M	1.37%	26

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

PAMU

Pictet Asset Management (UK) London, United Kingdom $91.8B AUM 47.77% 1-Year Est. Return

NorthCoast Asset Management's NBIX Position: Q1 2021 in Review

NorthCoast Asset Management sold out of Neurocrine Biosciences (NBIX) in Q1 2021, closing a stake of 4,195 shares — an estimated $402K sold.

NorthCoast Asset Management first reported a position in NBIX in Q3 2018 and held it in 5 quarters. The position peaked at $22.2M in Q3 2018. 419 funds tracked by Wall St. Rank hold NBIX as of Q1 2021.

NorthCoast Asset Management reported no remaining Neurocrine Biosciences position as of Q1 2021 after selling out during the quarter.
NorthCoast Asset Management sold 4,195 Neurocrine Biosciences shares in Q1 2021, an estimated $402K.
NorthCoast Asset Management first reported a position in Neurocrine Biosciences in Q3 2018 and held it in 5 quarters.
NorthCoast Asset Management's Neurocrine Biosciences position peaked at $22.2M in Q3 2018.
419 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2021.

Based on NorthCoast Asset Management's 13F filing for Q1 2021, filed 18 May 2021.